1. Home
  2. MLYS vs NSIT Comparison

MLYS vs NSIT Comparison

Compare MLYS & NSIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$27.18

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo Insight Enterprises Inc.

NSIT

Insight Enterprises Inc.

HOLD

Current Price

$74.11

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
NSIT
Founded
2019
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.1B
IPO Year
2023
1996

Fundamental Metrics

Financial Performance
Metric
MLYS
NSIT
Price
$27.18
$74.11
Analyst Decision
Strong Buy
Hold
Analyst Count
6
4
Target Price
$48.67
$118.75
AVG Volume (30 Days)
1.2M
382.0K
Earning Date
05-11-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
37.43
N/A
EPS
N/A
4.86
Revenue
N/A
$8,247,180,000.00
Revenue This Year
N/A
$3.79
Revenue Next Year
N/A
$2.16
P/E Ratio
N/A
$15.23
Revenue Growth
N/A
N/A
52 Week Low
$12.59
$63.62
52 Week High
$47.65
$148.36

Technical Indicators

Market Signals
Indicator
MLYS
NSIT
Relative Strength Index (RSI) 53.22 52.15
Support Level $26.85 $63.62
Resistance Level $31.09 $86.82
Average True Range (ATR) 1.65 3.45
MACD 0.38 1.15
Stochastic Oscillator 62.11 89.50

Price Performance

Historical Comparison
MLYS
NSIT

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About NSIT Insight Enterprises Inc.

Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, government agencies, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital workplace, cloud/data center transformation, IT modernization, Cyber Security and supply chain optimization solutions and services.

Share on Social Networks: